Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR3419 + Rituximab in Relapsed/Refractory DLBCL
NCT01470456Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2011
- Primary completion
- Jul 2013
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
A Phase 2 trial of coltuximab ravtansine in diffuse large B-cell lymphoma (DLBCL), sponsored by Sanofi. Started Nov 2011; status: completed.
02
Drugs
coltuximab ravtansine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01470456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01470456.